Publikace
- G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab2016 | 1. lékařská fakulta, Lékařská fakulta v Plzni
- Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC2016 | Lékařská fakulta v Plzni, Přírodovědecká fakulta
- Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib2016 | Lékařská fakulta v Plzni, Přírodovědecká fakulta
- The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy2016 | Lékařská fakulta v Plzni
- High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib2015 | 1. lékařská fakulta, Lékařská fakulta v Plzni, Přírodovědecká fakulta
- Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation2015 | Lékařská fakulta v Plzni, Přírodovědecká fakulta
- Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report2014 | Lékařská fakulta v Plzni
- The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer2013 | Lékařská fakulta v Plzni
- Gene Mutations in Squamous Cell NSCLC: Insignificance of EGFR, KRAS and PIK3CA Mutations in Prediction of EGFR-TKI Treatment Efficacy2013 | Lékařská fakulta v Plzni
- Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC2013 | Lékařská fakulta v Plzni
Loading network view...